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CaSe repOrtS

treatment of Cardiomyopathy with pap therapy in a patient
with Severe Obstructive Sleep apnea
Ritu G. Grewal, M.D.

Sleep Disorders Center, Thomas Jefferson University Hospital, Philadelphia, PA

Obstructive sleep apnea is common in patients with heart
failure. This case illustrates that treatment with PAP therapy
can improve cardiac function in patients with both conditions.
CPAP-emergent central apnea, as seen in this patient, has
multiple etiologies. It is commonly seen in patients with severe
sleep apnea, usually resolves over time, and does not need

treatment with adaptive servoventilation.
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Citation: Grewal RG. Treatment of cardiomyopathy with pap
therapy in a patient with severe obstructive sleep apnea. J Clin
Sleep Med 2012;8(5):581-583.

O

bstructive sleep apnea (OSA) is a common condition with
high rates of morbidity and mortality.1 The prevalence
of this disease has increased substantially, along with the cost
of diagnosing and treatment of this condition.2 Despite its association with cardiovascular diseases, sleep apnea remains
underdiagnosed in patients with heart disease.3,4 Meanwhile,
there has been increased development and promotion of new,
advanced, and more expensive devices by industry to treat
sleep apnea despite the lack of any evidence that these devices
have superior clinical outcomes.5 Following is a case which
highlights both these issues.

aspirin and maximal tolerated doses of ACE receptor inhibitor,
β-blocker, and a diuretic. An ICD (implantable cardioverterdefibrillator) was placed, and he was evaluated and placed on
the cardiac transplant list.
Due to his longstanding history of snoring, witnessed apneas, and excessive daytime sleepiness (Epworth Sleepiness
Scale [ESS] score of 17), he was evaluated for OSA in December 2008. Polysomnography, performed with a split-night
protocol revealed an apnea-hypopnea index (AHI) of 68 with
a SaO2 nadir of 58%. Respiratory events were all obstructive
in nature with no central apneas. Continuous positive airway
pressure (CPAP) titration to a maximum pressure of 20 cm
H2O was unsuccessful in controlling the obstructive respiratory events. He was also noted to develop central apneas, not
present on diagnostic polysomnography, along with a high leak
with increasing pressures. He was prescribed a bilevel device,
set at a maximum pressure of 25/21 cm water pressure, after a
retitration study in the sleep laboratory, during which a pressure of 28/23 cm water was insufficient to control obstructive
apneas and hypopneas. This was again associated with central
apneas on increasing the pressures (so called CPAP-emergent
central apnea). Significantly, he had evidence of high leak on
both titration studies.
On subsequent follow-up appointments, he demonstrated
fairly good compliance of > 80% with his bilevel device, despite complaints of dry mouth. He continued to have a high
leak, along with an elevated AHI of 15-17 on download of
smart card data. The patient had difficulty tolerating the high
pressures, and at one point tracheostomy was considered for
control of apneas but rejected by the transplant team due to fear
of infection following transplant, as the patient would be on
immunosuppressants.
He underwent an adaptive servoventilation (ASV) titration
study in October 2009. Expiratory positive airway pressure
(EPAP) was titrated to 18 cm water pressure with elimination
of all obstructive apneas and hypopneas. During this study he
had minimal leak and no evidence of central apneas as EPAP

repOrt Of CaSe
TC, a 44-year-old obese African American male with a BMI
of 41, longstanding history of hypertension, non-smoker, with
no history of alcohol use, and a 2-3 year history of progressively increasing shortness of breath and cough, was diagnosed
with New York Heart Association (NYHA) class III heart failure (HF) in July 2008. Electrocardiogram (ECG) findings were
notable for biatrial abnormality and borderline left ventricular
(LV) hypertrophy, with no evidence of heart block. Echocardiogram showed severe dilation and global hypokinesis of LV
with a LV ejection fraction (LVEF) of 10% and moderately reduced right ventricular (RV) function. Left heart catheterization did not show any occlusive coronary artery disease. Right
heart catheterization showed elevated right atrial (RA) pressure
at 17 mm Hg, pulmonary capillary wedge pressure (PCWP) of
30 mm Hg, pulmonary artery (PA) pressure of 74/30 mm Hg,
and severely reduced right ventricular (RV) function. Cardiopulmonary exercise test showed maximum oxygen consumption (VO2) of 12 cc/kg/minute. His clinical presentation was
consistent with idiopathic dilated cardiomyopathy of unknown
etiology. An endomyocardial biopsy was not performed to rule
out any treatable causes of heart failure, in keeping with current
recommendations by the American Heart Association/American college of Cardiology (AHA/ACC).6 He was treated with
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pressures were being increased. He was prescribed an ASV
machine, set with a minimum EPAP of 18 cm, maximum inspiratory positive airway pressure (IPAP) of 25 cm, minimum
pressure support (PS) of 0, maximum PS of 7, and a backup
respiratory rate of 10.
Despite all the problems with PAP therapy during this year,
his symptoms of OSA and heart failure improved. NYHA functional class improved from Class III to Class I over the next
year. VO2 increased from 12 cc/kg/min at initial evaluation to
20 cc/kg/min two years later. Repeat echocardiograms at periodic intervals showed gradually improving cardiac function.
Echocardiogram with Doppler done in June 2011 showed mild
global LV dysfunction, with a LVEF at 45% to 50%. There was
mild LA and LV enlargement. RA and RV were normal with
significant reduction of estimated PA systolic pressure to 30 mm
Hg. Daytime sleepiness was no longer present, with improvement of ESS to 5. He no longer required a cardiac transplant.
Download of smart card data on subsequent appointments
showed no leak, with complete control of apneas at an EPAP
average device pressure of 18 cm for ≤ 90% of time and average PS of 2. All breaths were patient triggered. In other words,
this device was functioning as a CPAP machine set at a fixed
pressure of 18 cm (minimum EPAP was set at 18), with no leak
and complete control of apneas.

were treated had a better 2-year survival rate than those who
were not treated.18
It is now recommended that physicians caring for patients
with heart failure need to be aware of the presence of OSA and
its effect on causing progression of heart failure, along with the
role of treatment of sleep apnea and other therapies for heart
failure.19,20 An expert consensus statement from the AHA/ACC
recommends that with the current epidemic of obesity, hypertension, and heart failure, the prevalence and consequences of
OSA are likely to increase. There needs to be an increased interaction between sleep specialists and cardiologists in diagnosing
and treating this condition.21
Second, this case also highlights a possible etiology of CPAP
-emergent central apnea. Several hypotheses have been proposed to explain CPAP-emergent central apnea; most of these
hypotheses suggest that CPAP -emergent central apnea resolves
over time.22 It has been shown in one study of patients with
both OSA and CHF to be related to a high respiratory controller
gain prior to application of CPAP.23 A high leak leading to CO2
washout could also be responsible. It may be due to the changes in CO2 excretion that occur with relief of the upper airway,
leading to a fall in pCO2 below the apneic threshold.24 Sleep
fragmentation with frequent sleep-wake transitions occurring
with initiation of CPAP can lead to central apneas.25 Adaptive
servoventilation (ASV) has been shown to be superior to CPAP
in treating central sleep apnea, but there have been no long-term
studies showing superior clinical outcomes.26,27 There are currently two ongoing multicenter, randomized controlled trials,
ADVENT-HF and SERVE-HF,31 to evaluate the cost effectiveness and efficacy of ASV in treating patients with heart failure
and central sleep apnea.
It is my view that this patient developed a dilated non-ischemic cardiomyopathy, most likely due to severe untreated OSA,
with hypertension and hypoxemia, present for many years. It is
possible that other etiologies of heart failure such as viral myocarditis, sarcoidosis, and rare conditions like amyloidosis and
hemochromatosis may have been present, and an endomyocardial biopsy would have better elucidated the cause of heart failure.6 However, the clinical scenario presented strongly suggests
that the cause of heart failure in this patient was obstructive
sleep apnea. Treatment of OSA with PAP therapy, along with
the associated improvement in hypoxemia, in conjunction with
medical therapy for hypertension and heart failure contributed
significantly to improved cardiac function to the extent that he
did not require a cardiac transplant.
With PAP therapy, he developed central apneas, possibly due
to a high leak. Over time, central apneas were no longer present as evidenced by smart card data with no use of PS (PS of 2
being insignificant) and all breaths being patient triggered. PAP
requirements to keep the upper airway open were reduced to a
much lower level along with minimal leak. This may have been
due to increased compliance and volume of the upper airway,28
partly due to improved ejection fraction, with reduced congestion of the upper airway. Reduced CPAP pressures requirements
may also be due to reduced collapsibility of the upper airway
with increasing lung volume from continued CPAP use,29 loss
of weight, and decreased heart size. It is possible that reduced
inflammation of the upper airway over time with CPAP use may
have played a role.28,30 It is important to note that this patient

DISCUSSION
This case is interesting because it highlights a number of important points. First is the association of obstructive sleep apnea
with heart failure. Sleep disordered breathing (OSA and central
sleep apnea) is common in patients with heart failure, but the
diagnosis is frequently missed, as the typical symptoms of OSA
may not be present.7 The prevalence can be as high as 50%
in patients with reduced ejection fraction.8 In the Sleep Heart
Health Study, a large prospective, multicenter observational cohort study over 9 years, obstructive sleep apnea was associated
with an increased risk of incident heart failure in both middleaged and elderly males and reduced survival in younger males.9
There was also a dose-response relationship, with a higher AHI
being associated with a greater risk of developing heart failure
as well as increased mortality. In one observational study of 296
patients with severely reduced cardiac function (median LVEF
of 33%), patients with severe sleep disordered breathing had a
2-fold increased risk for death, which improved in the patients
who were treated with CPAP.10
OSA may worsen cardiac function by increasing afterload
due to the negative intrathoracic pressure generated during respiratory efforts against an occluded upper airway.11 Sleep apnea has also been shown to cause progression of heart failure
possibly due to intermittent hypoxia.12,13 It is well known that
cardiac function improves with PAP therapy.14,15 This is not
only as a consequence of positive intrathoracic pressure reducing transmural pressure, which reduces afterload, but preload is
also reduced. Both lead to improvement in ejection fraction.16,17
In a retrospective study of over 30,719 Medicare beneficiaries
with heart failure, those who were tested, diagnosed, and treated for OSA had a better 2-year survival rate than subjects with
heart failure who were not tested for OSA. Similarly, among
subjects who were tested and diagnosed with OSA, those who
Journal of Clinical Sleep Medicine, Vol. 8, No. 5, 2012
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was treated with an ASV device, which eventually functioned
as a CPAP machine.
In conclusion, this case should heighten the awareness of
the association of heart failure and OSA. It also illustrates the
improvement in cardiac function with positive pressure therapy. CPAP-emergent central apnea has multiple etiologies, and
in most patients resolves over time, and does not need to be
treated. Finally, pressure requirements to treat severe OSA may
decrease over time.
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